RP CILIA
How to prevent retinal degeneration
Project description
This project involves the development of a pharmacological treatment to prevent retinal degeneration induced by ciliopathies. This condition is highly debilitating and manifests itself from childhood.
This treatment offers both the possibility of preventing the death of retinal cells and maintaining visual function in patients with this type of rare disease.
If the results are positive, this treatment could also be used for other diseases of this type such as Joubert's syndrome, Alström's disease...
Why does Conectus invest in this project?
Conectus' financial investment will make it possible to validate that the combination of molecules used works in vivo.
At the origin of the project:
Hélène Dollfus, Professor at the Laboratory of Medical Genetics
Focus
Conectus is investing in this project: €234,525
Duration: 18 months